Lung Cancer Clinical Trials

If you are an interested patient, researcher or sponsor, please feel free to call us at (845) 483-6825 or email

Open to Enrollment


Study Identifier: A151216 Alchemist
Principal Investigator: Cliff Connery, MD

Study Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Study Summary: A screening trial for patients with lower stage non-small cell lung cancer (NSCLC). Participants have genetic testing done to look for presence of one of two specific gene alterations, which may make them eligible for the E4512 or A081105 ALCHEMIST trials. If the alterations are absent, the patient is followed on the screening trial every six months or they may be eligible for the ANVIL trial.

Study Identifier: I-ELCAP
Study Investigator: Cliff Connery, MD

Study Summary: The purpose of this non-experimental study is to assess the efficacy of low dose, non-contrast computed tomographic (CT) examination of the lungs in detecting early lung cancer in individuals who are at high-risk for developing Lung Cancer. The study is part of the International Early Lung Cancer Action Program (I-ELCAP).

Study Identifier: A081105 Alchemist
Principal Investigator: Radhika Rachamalla, MD

Study Title: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Study Summary: The purpose of A081105 ALCHEMIST is to look at the usefulness of Erlotinib in early stage NSCLC in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC).

Study Identifier: E4512 Alchemist
Principal Investigator: Radhika Rachamalla, MD

Study Title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Study Summary:  The purpose of E4512 ALCHEMIST is to look at the usefulness of Crizotinib for patients with tumors harboring the anaplastic lymphoma kinases (ALK) fusion protein.

Study Identifier: NCT0466699
Principal Investigator: Faiz Y. Bhora, MBBS

Study Title: Intraoperative,Percutaneous Localization of Peripheral Pulmonary Nodules for Resection: AProspective, Open-Label, Multi-Center Registry Study of Thoracic SurgeryOutcomes (PLOTS Registry)

Study Summary: The PLOTS registry is a multi-institutional registry being conducted at 13 different hospitals across the United States. It aims to develop a high-quality set of data for localization techniques for peripheral pulmonary nodules (PPNs). Successful localization of PPNs presents as a challenge. In current practice, hard to see or palpate nodules are localized with dye and/or hook wires, or fiducials, either endoscopically or percutaneously. Successful, large, prospective studies have not been reported using modern electromagnetic navigation (EMN)-guided intraoperative, percutaneous localization, and different techniques (dye vs. fiducial vs. hook wire, etc.) have not been evaluated. It is for these reasons that data on the different localization techniques used with EMN-guided percutaneous localization will be collected for patients having a suspicious nodule, and who undergo intraoperative, percutaneous localization and immediate resection.

This registry aims to record the localization techniques used by thoracic surgeons and IP/surgical teams to identify PPNs using the SPiN Thoracic Navigation System™ in the hands of trained physicians.


Closed to Enrollment

Study Identifier: Alliance 211401 
Principal Investigator: Cliff Connery, MD

Study Title: Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes

 Study Summary: This randomized phase III trial studies how well management of a tobacco treatment intervention works in reducing surgical complications in patients with newly diagnosed lung cancer who smoke cigarettes. Management of a tobacco treatment intervention compares varenicline (a drug that reduces the craving and withdrawal symptoms that occur with abstinence from nicotine) and behavioral interventions (consisting of a brief clinician-delivered intervention and tobacco quitline [tobacco cessation service available through a toll-free telephone number] follow-up) with placebo (a pill with no active medication) along with similar behavioral interventions. It is not yet known whether management of a tobacco treatment intervention is more effective in reducing surgical complications than placebo.

Study Identifier: EA5142 ANVIL 
Principal Investigator: Radhika Rachamalla, MD

Study Title: Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL)

Study Summary: Patients in A151216 that do not have the ALK or EGFR mutation, are eligible for the ANVIL trial, which studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.

Study Type: Interventional

Study Identifier: I-ELCART
Study Investigator: Cliff Connery, MD

Study Summary: The Initiative for Early Lung Cancer Research for Treatment (IELCART) has as its broad research objective the advancement of knowledge about optimal treatment of clinical Stage IA lung cancer. It focuses on identifying optimal surgical treatment, but other treatment comparison (such as comparing surgery with stereotactic radiotherapy or watchful waiting) will be performed in the context protocol as well.

Study Identifier: RTOG 0813
Principal Investigator: Edward Farhangi, MD
Study Title: Stereotactic Body Radiation Therapy in Treating Patients with Stage I Non-Small Cell Lung Cancer

Study Summary: The purpose of the RTOG 0813 study is to study the side effects and best dose of a newer radiation treatment that gives fewer but higher doses of radiation known as stereotactic body radiation therapy and to see how well it works in treating patients with stage I non-small cell lung cancer that cannot be removed surgically.

Study Identifier: ECOG e1505
Principal Investigator: James M Leonardo, MD
Study Title: Chemotherapy With or Without Bevacizumab in Treating Patients with Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer that was Removed by Surgery

Study Summary: The purpose of the e1505 study is to compare the effects of adding bevacizumab to chemotherapy with standard chemotherapy alone, to see which is better at preventing lung cancer from coming back. Bevacizumab is investigational, which means it has not been approved by the FDA for use in this cancer.

Study Identifier: NEPTUNE 
Principal Investigator: Cliff Connery, MD
Study Title:  Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). (NEPTUNE)

Study Summary: This is a first-line treatment trial for patients that have advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type.. This study aims to determine the efficacy and safety of a combination immunotherapy (MEDI4736 + tremelimumab) versus platinum-based Standard of Care chemotherapy in this particular population. Study Type:  Randomized, open-label, multi-center, global, Phase III study.